Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Combination HIV-IG/Monoclonal Antibody Dose Neutralizes AIDS Virus WASHINGTON, Jan. 25, 1997 -- NABI (Nasdaq: NABI) A combination dose of two monoclonal antibodies (Mabs) and HIV-IG(TM), NABI's lead HIV immunotherapeutic, demonstrates significantly enhanced neutralization of the HIV virus. This data was presented today at the Fourth Conference on Retroviruses and Opportunistic Infections. John Mascola, M.D. of the Walter Reed Army Institute of Research and lead scientist on the study noted that a highly synergistic effect between HIV-IG and Mabs 2F5 and 2G12 appeared to be more successful in neutralizing HIV than either single or double combinations of the reagents. "Against most viruses tested, the effect of the combination was synergistic in neutralizing HIV infection of T lymphocytes. The neutralization was found in 13 of the 14 clade B strains of HIV1," Dr. Mascola said. Christine V. Sapan, Ph.D., Director of Scientific Affairs for NABI and co-author of the study, added, "The highly synergistic effect between HIV-IG and monoclonal antibodies suggests that we could use smaller quantities of HIV-IG in a new combination formulation. This new formulation could potentially expand the clinical reach of HIV-IG." David J. Gury, Chairman, President and CEO of NABI, added, "We are encouraged by this data, which represents another significant step in the development of our HIV-IG program." HIV-IG is being studied in two sets of clinical trials being conducted by the National Institutes of Health. HIV-IG, in conjunction with AZT, is undergoing Phase III studies to assess its efficacy in preventing HIV transmission from mother to infant. In a Phase II dosing trial, HIV-IG is being studied to determine its impact on children with AIDS. NABI, a fully integrated biopharmaceutical company, has a broad product portfolio and significant R&D capabilities focused on the development and commercialization of products that prevent and treat autoimmune and infectious diseases. NABI currently has 11 products in its clinical pipeline for indications including HIV; hepatitis viruses; staph infections; and cytomegalovirus. NABI also has two immunotherapeutic products already on the market: H-BIG(R), for the prevention of hepatitis B, and WinRho SD(R), for the treatment of Immune Thrombocytopenic Purpura [ITP, an immune platelet disorder], and for the suppression of Rh isoimmunization. E-mail this page to a friend or colleague! To print, use this version